^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

metatinib tromethamine (BMS-794833)

i
Other names: BMS-794833
Associations
Company:
Simcere
Drug class:
c-MET inhibitor
Related drugs:
Associations
9ms
BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway. (PubMed, J Bone Oncol)
Recently, several TKIs, for instance regorafenib and cabozantinib, have showed clinical interest in treating osteosarcoma and target both vascular endothelial growth factor receptor (VEGFR) and mesenchymal epithelial transition factor (c-MET)...More importantly, BMS-794833 and anlotinib exerted synergistic therapeutic effects against osteosarcoma in vivo. Altogether, this study reveals a new (VEGFR)-targeting drug that can be combined with anlotinib for the treatment of osteosarcoma, which provides an important theoretical basis for overcoming anlotinib resistance.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
Focus V (anlotinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • metatinib tromethamine (BMS-794833)
almost3years
Polypharmacological reprogramming of tumor-associated macrophages towards an inflammatory phenotype. (PubMed, Cancer Res)
BMS-794833, a multitargeted compound, was identified as a potent inhibitor of TAM polarization...The effect of BMS-794833 was independent of its primary targets (MET and VEGFR2) but was dependent on its effect on multiple signaling pathways, including focal adhesion kinases, SRC family kinases, STAT3, and p38 MAP kinases. Collectively, these findings underline the efficacy of polypharmacological strategies in reprogramming complex signaling cascades activated during TAM polarization.
Journal
|
KDR (Kinase insert domain receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
metatinib tromethamine (BMS-794833)
almost4years
Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial. (PubMed, Oncologist)
Metatinib administration of 200 mg/day was well tolerated, safe, and effective. The MTD was 200 mg/day, which should be recommended in further investigations.
Clinical • P1 data • PK/PD data • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • KDR (Kinase insert domain receptor)
|
MET overexpression • MET positive
|
metatinib tromethamine (BMS-794833)